📊 AURA Key Takeaways
Is Aura Biosciences, Inc. (AURA) a Good Investment?
Aura Biosciences is a pre-revenue biotech company with a fortress balance sheet ($84.8M cash, zero debt) providing approximately 2.8 years of runway at current burn rates. While the strong financial position mitigates immediate distress, the absence of revenue and negative $30M annual operating cash burn reflect typical early-stage clinical biotech dynamics that require clinical success and regulatory approval to justify investment.
Aura Biosciences remains a pre-revenue biotech with substantial operating and free cash flow losses, so the core fundamentals are still driven by cash consumption rather than commercial execution. The balance sheet is relatively clean, with strong liquidity and no meaningful debt, but profitability trends remain weak and the business still depends on pipeline progress and continued funding to sustain operations.
Aura Biosciences, Inc. Key Strengths (AURA)
- Exceptional cash position of $84.8M with zero long-term debt
- Outstanding liquidity with 7.09x current ratio reducing bankruptcy risk
- Conservative capital structure with stockholders' equity of $107.2M exceeding liabilities by 3.5x
- Adequate cash runway of 2-3 years at current burn rate without additional financing
- Strong liquidity profile with a 9.04x current and quick ratio
- Debt-free capital structure reduces financial leverage risk
- Solid equity base of $156.67M provides balance sheet support
AURA Stock Risks: Aura Biosciences, Inc. Investment Risks
- Complete absence of revenue indicating pre-commercialization stage with unproven market demand
- Significant cash burn of $29.9M annually depleting financial runway
- Clinical trial and regulatory approval risks inherent to biotech; failure would devastate company viability
- Likely requirement for substantial dilutive equity financing if clinical timelines extend or burn accelerates
- Total assets of only $137.7M provide limited financial cushion if development programs encounter setbacks
- No reported revenue, limiting visibility into commercial traction and growth quality
- Large net loss and negative operating cash flow indicate ongoing cash burn
- Cash and equivalents of $47.55M are below annual operating cash outflow, raising funding runway concerns
Key Metrics to Watch
- Clinical trial progression and regulatory milestone achievements
- Quarterly cash burn rate and projected runway extension/contraction
- Any revenue generation or partnership announcements indicating commercialization progress
- Capital raise requirements and dilution percentage
- Quarterly operating cash burn versus cash and equivalents
- Any emergence of collaboration revenue, product revenue, or major late-stage clinical progress
Aura Biosciences, Inc. (AURA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 7.09x current ratio provides a solid financial cushion.
AURA Profit Margin, ROE & Profitability Analysis
AURA vs Healthcare Sector: How Aura Biosciences, Inc. Compares
How Aura Biosciences, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Aura Biosciences, Inc. Stock Overvalued? AURA Valuation Analysis 2026
Based on fundamental analysis, Aura Biosciences, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Aura Biosciences, Inc. Balance Sheet: AURA Debt, Cash & Liquidity
AURA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Aura Biosciences, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.75 indicates the company is currently unprofitable.
AURA Revenue Growth, EPS Growth & YoY Performance
Aura Biosciences, Inc. Dividends, Buybacks & Capital Allocation
AURA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Aura Biosciences, Inc. (CIK: 0001501796)
📋 Recent SEC Filings
❓ Frequently Asked Questions about AURA
What is the AI rating for AURA?
Aura Biosciences, Inc. (AURA) has a Combined AI Grade of C from Claude (B) and ChatGPT (C) with 74% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are AURA's key strengths?
Claude: Exceptional cash position of $84.8M with zero long-term debt. Outstanding liquidity with 7.09x current ratio reducing bankruptcy risk. ChatGPT: Strong liquidity profile with a 9.04x current and quick ratio. Debt-free capital structure reduces financial leverage risk.
What are the risks of investing in AURA?
Claude: Complete absence of revenue indicating pre-commercialization stage with unproven market demand. Significant cash burn of $29.9M annually depleting financial runway. ChatGPT: No reported revenue, limiting visibility into commercial traction and growth quality. Large net loss and negative operating cash flow indicate ongoing cash burn.
What is AURA's revenue and growth?
Aura Biosciences, Inc. reported revenue of N/A.
Does AURA pay dividends?
Aura Biosciences, Inc. does not currently pay dividends.
Where can I find AURA SEC filings?
Official SEC filings for Aura Biosciences, Inc. (CIK: 0001501796) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is AURA's EPS?
Aura Biosciences, Inc. has a diluted EPS of $-0.50.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is AURA's fundamental grade?
Based on our AI fundamental analysis in June 2026, Aura Biosciences, Inc. has a C grade with 74% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is AURA stock overvalued or undervalued?
Valuation metrics for AURA: ROE of -31.4% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is AURA's AI grade for 2026?
Our dual AI analysis gives Aura Biosciences, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is AURA's free cash flow?
Aura Biosciences, Inc.'s operating cash flow is $-29.9M, with capital expenditures of $102.0K.
How does AURA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -31.4% (avg: 15%), current ratio 7.09 (avg: 2).